Alkermes plc — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · Ireland
Last price 45.34 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.61B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Details
| Name | Alkermes plc |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 2050 |
| Founded | 1987 |
| Ipo Date | 1991-07-16 |
| Ceo | Blair Jackson |
| Country | Ireland |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | IE00B56GVS15 |
| Cusip | G01767105 |
| Cik | 0001520262 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Blair C. Jackson | President, Chief Executive Officer and Director |
| Joshua Reed M.B.A. | Senior Vice President and Chief Financial Officer |
| David Joseph Gaffin J.D. | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary |
| Dr. Craig C. Hopkinson M.D. | Executive Vice President of Research and Development and Chief Medical Officer |
| Christian Todd Nichols | Senior Vice President and Chief Commercial Officer |
| Samuel J. Parisi | Interim Principal Accounting Officer and Vice President of Finance |
| Tom Skoff | SVice President and Chief Information Officer |
| Sandra Coombs | Senior Vice President of Corporate Affairs and Investor Relations |
| Stephen Schiavo | Senior Vice President and Chief Human Resources Officer |
| Peter Norman | SVice President of Policy, Government and Community Relations |
Contact
| Address | Connaught House, 1 Burlington Road, Dublin, D04 C5Y6, Ireland |
| Phone | 353 1 772 8000 |
| Website | https://www.alkermes.com |